ReportPhenformin (cas 114-86-3), But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation

Add time:08/22/2019    Source:sciencedirect.com

SummaryAMPK acts downstream of the tumor suppressor LKB1, yet its role in cancer has been controversial. AMPK is activated by biguanides, such as metformin and phenformin, and metformin use in diabetics has been associated with reduced cancer risk. However, whether this is mediated by cell-autonomous AMPK activation within tumor progenitor cells has been unclear. We report that T-cell-specific loss of AMPK-α1 caused accelerated growth of T cell acute lymphoblastic leukemia/lymphoma (T-ALL) induced by PTEN loss in thymic T cell progenitors. Oral administration of phenformin, but not metformin, delayed onset and growth of lymphomas, but only when T cells expressed AMPK-α1. This differential effect of biguanides correlated with detection of phenformin, but not metformin, in thymus. Phenformin also enhanced apoptosis in T-ALL cells both in vivo and in vitro. Thus, AMPK-α1 can be a cell-autonomous tumor suppressor in the context of T-ALL, and phenformin may have potential for the prevention of some cancers.

We also recommend Trading Suppliers and Manufacturers of Phenformin (cas 114-86-3). Pls Click Website Link as below: cas 114-86-3 suppliers

Prev:Adsorption of phenylhydrazine derivatives on hypercrosslinked polymeric adsorbents
Next:Original ArticleMelanocytes/MelanomaPhenformin (cas 114-86-3) Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma)